FMP
Myovant Sciences Ltd.
MYOV
NYSE
Inactive Equity
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
26.98 USD
-0.01 (-0.03706%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was ...
CIK
0001679082
ISIN
BMG637AM1024
CUSIP
G637AM102
Address
11-12 St. James’s Square
Phone
44 20 7400 3351
Country
GB
Employee
579
IPO Date
Oct 27, 2016
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
MYOV Financial Summary
CIK
0001679082
Exchange
NYSE
Industry
Biotechnology
Sector
Healthcare
CUSIP
G637AM102
ISIN
BMG637AM1024
Country
GB
Price
26.98
Beta
2.15
Volume Avg.
1.09M
Market Cap
2.62B
Shares
-
52-Week
7.67-27.06
DCF
34.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-14.05
P/B
-
Website
https://myovant.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MYOV News
It looks like there's no news available.
